PureTech Health, a clinical-stage biotherapeutics company, will advance therapeutic candidate LYT-300 (oral allopregnanolone) for the potential treatment of anxiety disorders and postpartum depression (PPD). A social anxiety clinical trial in healthy volunteers is expected to begin in the first half of 2023, with results anticipated by the end of 2023; a clinical trial in women […]
Menu ≡ ╳ 
